logo
Participants in the Davos, Switzerland, Meeting, February 15-16, 1997
Introduction
Fundamentals of coagulation and glycoprotein IIb/IIIa receptor inhibition
An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors
Rationale and clinical evidence for the use of GP IIb/IIIa inhibitors in acute coronary syndromes
Use of abciximab in interventional cardiology
Safe use of platelet GP IIb/IIIa inhibitors
Abciximab therapy in percutaneous intervention: Economic issues in the United States
Costs and effects in therapy for acute coronary syndromes: The case of abciximab in high-risk patients undergoing percutaneous transluminal coronary angioplasty in the EPIC study